Extrahepatic Manifestations of Primary Biliary Cholangitis

키워드

참고문헌 (108)

1. Lee J, "Transplantation trends in primary biliary cirrhosis", Clin Gastroenterol Hepatol, 5, pp.1313~1315 (2007)
2. Poupon RE, "Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis", Gastroenterology, 113, pp.884~890 (1997)
3. Lindor KD, "Primary biliary cirrhosis", Hepatology, 50, pp.291~308 (2009)
4. Gershwin ME, "Primary biliary cirrhosis: paradigm or paradox for autoimmunity", Gastroenterology, 100, pp.822~833 (1991)
5. Selmi C, "Epidemiology and pathogenesis of primary biliary cirrhosis", J Clin Gastroenterol, 38, pp.264~271 (2004)
6. Boonstra K, "Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review", J Hepatol, 56, pp.1181~1188 (2012)
7. Selmi C, "Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment", Gastroenterology, 127, pp.485~492 (2004)
8. Bach N, "Familial primary biliary cirrhosis", J Hepatol, 20, pp.698~701 (1994)
9. Witt-Sullivan H, "The demography of primary biliary cirrhosis in Ontario, Canada", Hepatology, 12, pp.98~105 (1990)
10. Carbone M, "The effect of liver transplantation on fatigue in patients with primary biliary cirrhosis: a prospective study", J Hepatol, 59, pp.490~494 (2013)
11. Carey EJ, "Primary biliary cirrhosis", Lancet, 386, pp.1565~1575 (2015)
12. Dyson JK, "Novel therapeutic targets in primary biliary cirrhosis", Nat Rev Gastroenterol Hepatol, 12, pp.147~158 (2015)
13. Selmi C, "Primary biliary cirrhosis and Sjögren’s syndrome: autoimmune epithelitis", J Autoimmun, 39, pp.34~42 (2012)
14. Sorokin A, "Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review", Atherosclerosis, 194, pp.293~299 (2007)
15. Longo M, "Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis", Gut, 51, pp.265~269 (2002)
16. Crippin JS, "Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk", Hepatology, 15, pp.858~862 (1992)
17. Kaplan MM, "Fat-soluble vitamin nutriture in primary biliary cirrhosis", Gastroenterology, 95, pp.787~792 (1988)
18. Raszeja-Wyszomirska J, "Osteoporosis in primary biliary cirrhosis of the liver", Prz Gastroenterol, 9, pp.82~87 (2014)
19. Guañabens N, "Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis", J Hepatol, 42, pp.573~577 (2005)
20. Marasini B, "Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients", Ann Rheum Dis, 60, pp.1046~1049 (2001)
21. Gershwin ME, "Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients", Hepatology, 42, pp.1194~1202 (2005)
22. Inoue K, "Prediction of prognosis of primary biliary cirrhosis in Japan", Liver, 15, pp.70~77 (1995)
23. Silveira MG, "Thyroid dysfunction in primary biliary cirrhosis, primary sclerosing cholangitis and non-alcoholic fatty liver disease", Liver Int, 29, pp.1094~1100 (2009)
24. Tsianos EV, "Sjögren’s syndrome in patients with primary biliary cirrhosis", Hepatology, 11, pp.730~734 (1990)
25. Floreani A, "Extrahepatic autoimmune conditions associated with primary biliary cirrhosis", Clin Rev Allergy Immunol, 48, pp.192~197 (2015)
26. Culp KS, "Autoimmune associations in primary biliary cirrhosis", Mayo Clin Proc, 57, pp.365~370 (1982)
27. Mang FW, "Primary biliary cirrhosis, sicca complex, and dysphagia", Dysphagia, 12, pp.167~170 (1997)
28. Golding PL, "“Sicca complex” in liver disease", Br Med J, 4, pp.340~342 (1970)
29. Uddenfeldt P, "Features of Sjögren’s syndrome in patients with primary biliary cirrhosis", J Intern Med, 230, pp.443~448 (1991)
30. Vitali C, "Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group", Ann Rheum Dis, 61, pp.554~558 (2002)
31. Patel R, "The epidemiology of Sjögren’s syndrome", Clin Epidemiol, 6, pp.247~255 (2014)
32. Reksten TR, "Sjögren’s syndrome: an update on epidemiology and current insights on pathophysiology", Oral Maxillofac Surg Clin North Am, 26, pp.1~12 (2014)
33. Voulgarelis M, "Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome", Medicine (Baltimore), 91, pp.1~9 (2012)
34. Papageorgiou A, "Predicting the outcome of Sjogren’s syndrome-associated non-Hodgkin’s lymphoma patients", PLoS One, 10, pp.e0116189~ (2015)
35. Fallah M, "Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study", Ann Oncol, 25, pp.2025~2030 (2014)
36. Shiboski SC, "American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort", Arthritis Care Res (Hoboken), 64, pp.475~487 (2012)
37. Mavragani CP, "Sjögren syndrome", CMAJ, 186, pp.E579~E586 (2014)
38. Mavragani CP, "Conventional therapy of Sjogren’s syndrome", Clin Rev Allergy Immunol, 32, pp.284~291 (2007)
39. Crowe JP, "Primary biliary cirrhosis: the prevalence of hypothyroidism and its relationship to thyroid autoantibodies and sicca syndrome", Gastroenterology, 78, pp.1437~1441 (1980)
40. Elta GH, "Increased incidence of hypothyroidism in primary biliary cirrhosis", Dig Dis Sci, 28, pp.971~975 (1983)
41. Hollowell JG, "Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III)", J Clin Endocrinol Metab, 87, pp.489~499 (2002)
42. Biró E, "Association of systemic and thyroid autoimmune diseases", Clin Rheumatol, 25, pp.240~245 (2006)
43. Huang MJ, "Clinical associations between thyroid and liver diseases", J Gastroenterol Hepatol, 10, pp.344~350 (1995)
44. Sakauchi F, "A cross-sectional study of primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid", J Epidemiol, 15, pp.24~28 (2005)
45. Powell FC, "Primary biliary cirrhosis and the CREST syndrome: a report of 22 cases", Q J Med, 62, pp.75~82 (1987)
46. Nieri S, "Salvadori G, Surrenti C. Primary biliary cirrhosis and Graves’ disease", J Clin Gastroenterol, 7, pp.434~437 (1985)
47. Vanderpump MP, "The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey", Clin Endocrinol (Oxf), 43, pp.55~68 (1995)
48. Jacobson DL, "Epidemiology and estimated population burden of selected autoimmune diseases in the United States", Clin Immunol Immunopathol, 84, pp.223~243 (1997)
49. Caturegli P, "Hashimoto thyroiditis: clinical and diagnostic criteria", Autoimmun Rev, 13, pp.391~397 (2014)
50. Nyström HF, "Incidence rate and clinical features of hyperthyroidism in a long-term iodine sufficient area of Sweden (Gothenburg) 2003-2005", Clin Endocrinol (Oxf), 78, pp.768~776 (2005)
51. Burch HB, "Management of Graves disease: a review", JAMA, 314, pp.2544~2554 (2015)
52. LeRoy EC, "Scleroderma (systemic sclerosis): classification, subsets and pathogenesis", J Rheumatol, 15, pp.202~205 (1988)
53. Sharif R, "Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS cohort", Semin Arthritis Rheum, 41, pp.38~47 (2011)
54. Buck U, "Factors related to self-efficacy in persons with scleroderma", Musculoskeletal Care, 8, pp.197~203 (2010)
55. Thoua NM, "Assessment of gastrointestinal symptoms in patients with systemic sclerosis in a UK tertiary referral centre", Rheumatology (Oxford), 49, pp.1770~1775 (2010)
56. Roberts CG, "A case-control study of the pathology of oesophageal disease in systemic sclerosis (scleroderma)", Gut, 55, pp.1697~1703 (2006)
57. Tyndall AJ, "Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database", Ann Rheum Dis, 69, pp.1809~1815 (2010)
58. Walker UA, "Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database", Ann Rheum Dis, 66, pp.754~763 (2007)
59. Steen VD, "Severe organ involvement in systemic sclerosis with diffuse scleroderma", Arthritis Rheum, 43, pp.2437~2444 (2000)
60. Avouac J, "Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies", J Rheumatol, 37, pp.2290~2298 (2010)
61. Hachulla E, "Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study", Arthritis Rheum, 52, pp.3792~3800 (2005)
62. Avouac J, "Expert consensus for performing right heart catheterisation for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis", Ann Rheum Dis, 73, pp.191~197 (2014)
63. Allanore Y, "Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis", Ann Rheum Dis, 69, pp.218~221 (2010)
64. West SG, "Association of myositis and myocarditis in progressive systemic sclerosis", Arthritis Rheum, 24, pp.662~668 (1981)
65. Follansbee WP, "Cardiac and skeletal muscle disease in systemic sclerosis (scleroderma): a high risk association", Am Heart J, 125, pp.194~203 (1993)
66. Denton CP, "Renal complications and scleroderma renal crisis", Rheumatology (Oxford), 48(Suppl 3), pp.iii32~iii35 (2009)
67. van den Hoogen F, "2013 classification criteria for systemic sclerosis: an American college of rheumatology", European league against rheumatism collaborative initiative, 2013, pp.72, 1747~1755
68. Kowal-Bielecka O, "Scleroderma-modern aspects of pathogenesis, diagnosis and therapy", pp.89~95 (2009), Uni-Med Verlag AG
69. Bowling JC, "Raynaud’s disease", Lancet, 361, pp.2078~2080 (2003)
70. Shah AA, "My approach to the treatment of scleroderma", Mayo Clin Proc, 88, pp.377~393 (2013)
71. Kowal-Bielecka O, "Use of methotrexate in patients with scleroderma and mixed connective tissue disease", Clin Exp Rheumatol, 28(5 Suppl 61), pp.S160~S163 (2010)
72. Le EN, "Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis", Ann Rheum Dis, 70, pp.1104~1107 (2011)
73. Mendoza FA, "A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset", J Rheumatol, 39, pp.1241~1247 (2012)
74. Jordan S, "Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group", Ann Rheum Dis, 74, pp.1188~1194 (2015)
75. Barnett AJ, "The diagnosis and classification of scleroderma (systemic sclerosis)", Postgrad Med J, 64, pp.121~125 (1988)
76. Ferri C, "Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients", Medicine (Baltimore), 81, pp.139~153 (2002)
77. Meyer OC, "Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis", J Rheumatol, 34, pp.104~109 (2007)
78. Hunzelmann N, "Organ-specific diagnosis in patients with systemic sclerosis: Recommendations of the German Network for Systemic Sclerosis (DNSS)", Z Rheumatol, 67, pp.334~340 (2008)
79. Assassi S, "Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients", J Rheumatol, 36, pp.2250~2256 (2009)
80. Rigamonti C, "Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis", Gut, 55, pp.388~394 (2006)
81. Watt FE, "Patterns of autoimmunity in primary biliary cirrhosis patients and their families: a population-based cohort study", QJM, 97, pp.397~406 (2004)
82. Le Guern V, "Prevalence of systemic sclerosis in a French multi-ethnic county", Rheumatology (Oxford), 43, pp.1129~1137 (2004)
83. Chifflot H, "Incidence and prevalence of systemic sclerosis: a systematic literature review", Semin Arthritis Rheum, 37, pp.223~235 (2008)
84. Tan EM, "Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome", Arthritis Rheum, 23, pp.617~625 (1980)
85. Reveille JD, "American College of Rheumatology Ad Hoc Committee of Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies", Arthritis Rheum, 49, pp.399~412 (2003)
86. Powell FC, "The anticentromere antibody: disease specificity and clinical significance", Mayo Clin Proc, 59, pp.700~706 (1984)
87. Bernstein RM, "Anticentromere antibody in primary biliary cirrhosis", Ann Rheum Dis, 41, pp.612~614 (1982)
88. Hansen BU, "High prevalence of autoimmune liver disease in patients with multiple nuclear dot, anti-centromere, and mitotic spindle antibodies", Scand J Gastroenterol, 26, pp.707~713 (1991)
89. Chan HL, "Anticentromere antibodies (ACA): clinical distribution and disease specificity", Clin Exp Dermatol, 19, pp.298~302 (1994)
90. LeRoy EC, "Sentinel signs and symptoms of systemic sclerosis", Curr Opin Rheumatol, 2, pp.942~946 (1990)
91. Tashkin DP, "Cyclophosphamide versus placebo in scleroderma lung disease", N Engl J Med, 354, pp.2655~2666 (2006)
92. Walker KM, "participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG). Treatment of systemic sclerosis complications: what to use when first-line treatment fails: a consensus of systemic sclerosis experts", Semin Arthritis Rheum, 42, pp.42~55 (2012)
93. Dheda K, "Experience with azathioprine in systemic sclerosis associated with interstitial lung disease", Clin Rheumatol, 23, pp.306~309 (2004)
94. Bérezné A, "Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study", J Rheumatol, 35, pp.1064~1072 (2008)
95. Galiè N, "Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)", Eur Heart J, 30, pp.2493~2537 (2009)
96. Nakanishi N, "2009 ESC", ERS Pulmonary Hypertension Guidelines and connective tissue disease, 2011, pp.60, 419~424
97. Steen VD, "Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis", Arthritis Rheum, 41, pp.1613~1619 (1998)
98. Saketkoo LA, "The primary care physician in the early diagnosis of systemic sclerosis: the cornerstone of recognition and hope", Am J Med Sci, 347, pp.54~63 (2014)
99. Caramella C, "Association between rheumatoid arthritis and primary biliary cirrhosis", Joint Bone Spine, 74, pp.279~281 (2007)
100. Iliffe GD, "Primary biliary cirrhosis associated with features of systemic lupus erythematosus", Dig Dis Sci, 27, pp.274~278 (1982)
101. Sorensen HT, "Risk of primary biliary liver cirrhosis in patients with coeliac disease: Danish and Swedish cohort data", Gut, 44, pp.736~738 (1999)
102. Kingham JG, "The association between primary biliary cirrhosis and coeliac disease: a study of relative prevalences", Gut, 42, pp.120~122 (1998)
103. Bardella MT, "Screening patients with celiac disease for primary biliary cirrhosis and vice versa", Am J Gastroenterol, 92, pp.1524~1526 (1997)
104. Volta U, "Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune hepatitis", Dig Dis Sci, 43, pp.2190~2195 (1998)
105. Habior A, "Association of coeliac disease with primary biliary cirrhosis in Poland", Eur J Gastroenterol Hepatol, 15, pp.159~164 (2003)
106. Tada F, "Ulcerative colitis complicated with primary biliary cirrhosis", Intern Med, 50, pp.2323~2327 (2011)
107. Xiao WB, "Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature", World J Gastroenterol, 9, pp.878~880 (2003)
108. Muratori P, "Autoimmune liver disease and concomitant extrahepatic autoimmune disease", Eur J Gastroenterol Hepatol, 27, pp.1175~1179 (2015)

관련 논문AI추천